A5102904875- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- MicroRNA in disease regulation
- Salivary Gland Disorders and Functions
- Single-cell and spatial transcriptomics
- RNA modifications and cancer
- Cancer-related Molecular Pathways
- Advanced Fluorescence Microscopy Techniques
- Ocular Surface and Contact Lens
- Allergic Rhinitis and Sensitization
- Eosinophilic Disorders and Syndromes
- Respiratory Support and Mechanisms
- Electrospun Nanofibers in Biomedical Applications
- Lymphoma Diagnosis and Treatment
- Otitis Media and Relapsing Polychondritis
- Tissue Engineering and Regenerative Medicine
- Cancer-related molecular mechanisms research
- PI3K/AKT/mTOR signaling in cancer
- Effects and risks of endocrine disrupting chemicals
- Drug-Induced Adverse Reactions
- Cell Image Analysis Techniques
- RNA Research and Splicing
- Acute Lymphoblastic Leukemia research
- Carcinogens and Genotoxicity Assessment
- Hematopoietic Stem Cell Transplantation
Novartis Institutes for BioMedical Research
2018-2024
Novartis (Switzerland)
2017-2024
Philip Morris International (Switzerland)
2015-2016
ENT and Allergy
2011
Medizinische Hochschule Hannover
2010
Objectives To evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary Sjögren’s syndrome (pSS) double-blind, placebo-controlled, phase II, single-centre study. Methods Patients pSS, EULAR Syndrome Disease Activity Index (ESSDAI) ≥6, were randomised to single infusion at either 3 mg/kg (n=6), 10 (n=12) or placebo (n=9). Outcomes measured blinded baseline weeks 6, 12, 24,...
Abstract Safe and effective new oral therapies for autoimmune, allergic, inflammatory conditions remain a significant therapeutic need. Here, we investigate the human pharmacokinetics, pharmacodynamics (PDs), safety of selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor, remibrutinib. Study objectives were explored in randomized single multiple ascending dose (SAD MAD, respectively) cohorts with daily doses up to 600 mg, crossover food effect (FE) cohort, adult healthy subjects...
The Basophil Activation Test (BAT) enables flow cytometry characterization of basophil reactivity against specific allergenic molecules. focus now revolves around democratizing this tool, but, as blood sample stability could be challenging, after having developed a simplified approach, herein, we aimed to characterize two strategies for implementing BAT in multicentric studies: store and ship before or processing. Fresh heparin- EDTA-anticoagulated whole samples followed both workflows:...
Introduction: Cyt-Geist: Current and Future Challenges in Cytometry 601 Chapter 01: Trends 01 Introduction WS18: Flow Drivers WS06: the Era of Human Cell Atlas 000 WS07: CYTO Lab Hacks: Inspiring Innovation Through Open Collaboration 605 WS15: The Status Microbiome 607 Conclusion 610 02: Shared Resource Laboratory (SRL) Best Practices 02 WS01: Balancing Science Service a 611 WS02: A Successful Imaging Facility: Guidelines for Management Publication 613 WS05: Identification Areas Where...
Mouse models are useful for studying cigarette smoke (CS)-induced chronic pulmonary pathologies such as lung emphysema. To enhance translation of large-scale omics data from mechanistic studies into pathophysiological changes, we have developed computational tools based on reverse causal reasoning (RCR). In the present study applied a systems biology approach leveraging RCR to identify molecular explanations changes associated with CS-induced emphysema in susceptible mice. The transcriptomes...
<h3>Background</h3> Primary Sjögren's syndrome (pSS) is a systemic and progressive autoimmune disease characterised by lymphoid infiltration alteration of exocrine glands secretory function. Ectopic germinal center-like structures harbour plasma cells that generate autoantibodies leading to immune complex formation. Leniolisib (CDZ173) an oral low molecular weight compound selectively inhibits the lipid kinase PI3Kδ. In animals, leniolisib blocks PI3Kδ-dependent B cell functions, disrupts...
As with many aspects of the validation and monitoring flow cytometric methods, method transfer processes acceptance criteria described for other technologies are not fully applicable. This is due to complexity highly configurable instrumentation, cellular measurands, lack qualified reference materials most assays, limited specimen stability. There multiple reasons initiating a transfer, regulatory settings, context use. All these factors influence specific requirements transfer....
Abstract MYC transcription factors are well-established drivers of human cancers but despite being amongst the most frequently altered oncogenes, no approved therapy targeting MYC-driven tumors has been developed to date. known be addicted protein translation. This addiction creates a dependency on critical components translational machinery providing in turn unique opportunity for therapeutic intervention. We hypothesized that translation termination factor GSPT1, key regulator synthesis,...
Abstract MYC transcription factors have been demonstrated to be drivers of many cancers, yet remained recalcitrant new drug development. We hypothesized that MYC-driven cancer cell lines are addicted protein translation, and therefore vulnerable the loss translation termination factor, GSPT1. discovered MRT-2359, a selective GSPT1 molecular glue degrader, demonstrates potent preferential antiproliferative activity in lines, such as high N- L-MYC mRNA expressing non-small lung (NSCLC) small...
<b>Background:</b> Eosinophils (eos) are key inflammatory cells in asthma and they known to carry the Prostaglandin D2 receptor 2 (DP2). DP2 antagonists currently being developed for induce a reduction of lung eos. It is assumed that DP2+ eos mode action antagonists. <b>Aims:</b> In this study, expression on peripheral blood additional children (1 3 years) adults (≥18 65 was analyzed support treatment rationale with asthma. <b>Methods:</b> Twenty healthy – 23 were enrolled. The frequency (%)...